Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + ABVD for Hodgkin's Disease
NCT00504504Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2001
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Hodgkin lymphoma (HL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Failure-free Survival Rate at 5 years, Feasibility of Rituximab + ABVD and 2 more. Started Mar 2001; status: completed.
02
Drugs
rituximab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00504504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504504.